Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients

Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients

Aim: To study the signature of 87 urinary miRNAs in Duchenne muscular dystrophy (DMD) patients, select the most dysregulated and determine statistically significant differences in their expression between controls, ambulant (A) and nonambulant (NA) DMD patients, and patients on different corticoster...

Full description

Bibliographic Details
Main Authors:	Catapano, F, Domingos, J, Perry, M, Ricotti, V, Phillips, L, Servais, LJP, Seferian, A, de Groot, I, Krom, YD, Niks, EH, Verschuuren, JJ, Straub, V, Voit, T, Morgan, J, Muntoni, F
Format:	Journal article
Language:	English
Published:	Future Medicine 2018

Similar Items

Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study
by: Ricotti, V, et al.
Published: (2019)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
by: Frank, DE, et al.
Published: (2020)

Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
by: Vandana Ayyar Gupta, et al.
Published: (2023-01-01)

Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy.
by: Vandana Ayyar Gupta, et al.
Published: (2023-01-01)

Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
by: Francesco Muntoni, et al.
Published: (2024-01-01)

Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study
by: Muntoni, F, et al.
Published: (2024)

Mortality cost of Duchenne muscular dystrophy
by: Erik Landfeldt, et al.
Published: (2017-04-01)

Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
by: Fatima Amor, et al.
Published: (2021-06-01)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
by: Pietro Spitali, et al.
Published: (2018-08-01)

Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
by: Straub, V, et al.
Published: (2016)

Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (1989-05-01)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
by: Mirko Signorelli, et al.
Published: (2020-04-01)

Meaningful changes in motor function in Duchenne muscular dystrophy (DMD): A multi-center study.
by: Francesco Muntoni, et al.
Published: (2024-01-01)

Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy.
by: Irina T Zaharieva, et al.
Published: (2013-01-01)

Preserved thenar muscles in non‐ambulant Duchenne muscular dystrophy patients
by: Karin J. Naarding, et al.
Published: (2021-06-01)

Duchenne muscular dystrophy: recent insights in brain related comorbidities
by: Cyrille Vaillend, et al.
Published: (2025-02-01)

Muscular Fatigue in Duchenne Dystrophy
by: J Gordon Millichap
Published: (1995-02-01)

Glucocorticoids for Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (2013-07-01)

Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
by: Servais, L, et al.
Published: (2019)

Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up.
by: M T Hooijmans, et al.
Published: (2017-01-01)

Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy
by: Mary Chesshyre, et al.
Published: (2022-04-01)

Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In
by: Popplewell, L, et al.
Published: (2013)

Imaging biomarkers for Duchenne muscular dystrophy
by: Koppaka, Sisir
Published: (2017)

Progress in therapy for Duchenne muscular dystrophy.
by: Fairclough, R, et al.
Published: (2011)

Molecular genetics of Duchenne muscular dystrophy.
by: Kunkel, L, et al.
Published: (1986)

Progress in therapy for Duchenne muscular dystrophy
by: Fairclough, R, et al.
Published: (2011)

Utrophin upregulation in Duchenne muscular dystrophy.
by: Hirst, R, et al.
Published: (2005)

Utrophin in the therapy of Duchenne Muscular Dystrophy
by: Potter, A, et al.
Published: (2006)

Therapeutic approaches for Duchenne muscular dystrophy
by: Roberts, TC, et al.
Published: (2023)

Regenerative biomarkers for Duchenne muscular dystrophy
by: Guiraud, S, et al.
Published: (2019)

Deletion analysis of Duchenne muscular dystrophy
by: H Erdem, et al.
Published: (1993-01-01)

Orthopaedic Management in Duchenne Muscular Dystrophy
by: Uma Balachandran, BA, et al.
Published: (2025-02-01)

BREAKTHROUGH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT
by: article Editorial
Published: (2022-07-01)

Early Development in Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (1990-07-01)

Delay in Diagnosis of Duchenne Muscular Dystrophy
by: Vamshi K Rao, et al.
Published: (2015-01-01)

Prednisone-Treated Duchenne Muscular Dystrophy
by: J Gordon Millichap
Published: (1991-06-01)

Language Delay in Duchenne’s Muscular Dystrophy
by: J Gordon Millichap
Published: (2007-06-01)

Brain Function in Duchenne Muscular Dystrophy
by: J. Gordon Millichap
Published: (2002-02-01)

Epilepsy in Duchenne and Becker muscular dystrophies
by: Jesus Alfonso Armijo Gómez, et al.
Published: (2024-06-01)

Cognition trajectory in Duchenne muscular dystrophy
by: Abeer A. Tony, et al.
Published: (2024-07-01)